Impact of intravenous laser blood irradiation on the time course of changes in some cytokine profile indicators and cortisol and melatonin levels in patients with rheumatoid arthritis

DOI: https://doi.org/10.29296/25877305-2022-10-17
Issue: 
10
Year: 
2022

Z. Tsagaraeva, Candidate of Medical Sciences; N. Burduli, Candidate of Medical Sciences; Professor N. Burduli, MD; Z. Brtsieva, Candidate of Medical Sciences; M. Brtsieva; D. Bestaev, MD
North Ossetian State Medical Academy, Ministry of Health of Russia, Vladikavkaz

Rheumatoid arthritis (RA) lowers quality of life and contributes to early disability in able-bodied patients. Non-drug therapy for RA, which includes intravenous laser blood irradiation, is an additional procedure that can improve the patient’s health and functional status. Objective. To study the time course of changes in some cytokine profile indicators and melatonin and cortisol levels in patients with RA when intravenous laser blood irradiation is incorporated into the therapy. Subjects and methods. A total of 112 patients with RA were examined. The diagnosis was established according to the ACR/EULAR criteria. The patients were divided into 2 groups: a study group of patients who received an intravenous laser therapy cycle in addition to intravenous laser therapy and a control group of those who had traditional drug therapy only. The cycle of intravenous laser therapy was performed using a Matrix-ILBI device (Matrix, Russia) and consisted of 10 sessions. Conclusion. The findings may state that combination therapy using intravenous laser blood irradiation is accompanied by the elimination of an imbalance ratio of pro-inflammatory to anti-inflammatory cytokines and also causes a decrease in melatonin levels and an increase in cortisol ones.
Keywords: 
rheumatology
endocrinology
rheumatoid arthritis
cytokines
cortisol
melatonin
intravenous laser blood irradiation

References: 
  1. Pogozeva E.Y., Karateev A.E., Karateev D.E. Melatonin M. Its role in regulation of circadian rhythm of inflammatory reaction in rheumatoid arthritis. Rheumatology Science and Practice. 2008; 46 (3): 54–61 (in Russ.). DOI: 10.14412/1995-4484-2008-660
  2. McInnes I., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007; 7 (6): 429–42. DOI: 10.1038/nri2094
  3. Vakulenko O.Yu., Goryachev D.V., Krichevskaya O.A. et al. Evaluation of a decrese in work productivity in patients with rheumatoid arthritis. Rheumatology Science and Practice. 2013; 51 (6): 671–9 (in Russ.). DOI: 10.14412/1995-4484-2013-671-9
  4. Wysocka-Skurska I., Sierakowska M., Kułak W. Evaluation of Quality of Life in Chronic, Progressing Rheumatic Diseases Based on the Example of Osteoarthritis and Rheumatoid Arthritis. Clin Interv Aging. 2016; 11: 1741–50. DOI: 10.2147/CIA.S116185
  5. Bestaev D.V., Bozhyeva L.A., Nikonorova N.O. et al. Comparative clinical, laboratory, and instrumental evaluation of interstitial lung changes in rheumatoid arthritis. Rheumatology Science and Practice. 2014; 52 (3): 277–82 (in Russ.). DOI: 10.14412/1995-4484-2014-277-282
  6. Russian clinical guidelines. Rheumatology. Ed. E.L. Nasonov. M.: GEOTAR-Media, 2017; р. 17–57 (in Russ.).
  7. Smolen J.S., Aletaha D., McInnes I.B. Rheumatoid arthritis. Lancet. 2016; 388 (10055): 2023–38. DOI: 10.1016/S0140-6736(16)30173-8
  8. Trofimov D.Yu., Burmenskaya O.V., Bateneva E.I. et al. Development of a real-time RT-PCR-based test panel for assessment of cytokine profile in mononuclear cells from blood and synovial fluid in rheumatoid arthritis. Medical Immunology (Russia). 2008; 10 (6): 563–70 (in Russ.). DOI: 10.15789/1563-0625-2008-6-563-570
  9. Karateev A.E., Karateev D.E., Luchihina E.L. et al. The first experience of melatonin administration for correction of sleep disturbances in rheumatoid arthritis patients. Rheumatology Science and Practice. 2004; 42 (4): 73–6 (in Russ.). DOI: 10.14412/1995-4484-2004-807
  10. Cutolo M., Villaggiо B., Otsa K. et al. Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease’s symptoms. Autoimmun Rev. 2005; 4 (8): 497–502. DOI: 10.1016/j.autrev.2005.04.019
  11. Mendel O.I., Mendel V.E. Melatonin: the role in the body and therapeutic possibilities. Experience of using the drug Melaxen in Russian medical practice. RMJ. 2010; 6: 336 (in Russ.).
  12. Karateev D. Rituximab In The Current Therapy Of Rheumatoid Arthritis. Farmateka. 2010; 5: 26–32 (in Russ.).
  13. Mazurov V.I., Avlokhova S.R. The quality of life in patients with rheumatoid arthritis treated with rituximab. Clinical Medicine (Russian Journal). 2014; 12: 42–48(in Russ.).
  14. Kulova L.A., Burduli N.M. The effectiveness of low-level laser irradiation at the cellular interactions, endothelial functions, and hemostatic system in patients with rheumatoid arthritis. Laser Medicine. 2014; 18 (2): 5–7 (in Russ.).
  15. Khachkinaev G.A., Lysenko I.E., Sokolov I.O. et al. Analysis of the response to basic anti-inflammatory therapy in early rheumatoid arthritis and the possibility of a differentiated approach to the choice of drugs. Lechashchii vrach. 2011; 7: 79–83 (in Russ.).
  16. Ilyenkova N.A. Inflammatory cytokine levels in the blood and in expired air condensate from children with acute bronchitis and pneumonia. Russian Bulletin of Perinatology and Pediatrics. 2006; 3: 61–2 (in Russ.).